Chin-Chuan Hung

Prof. Chin-Chuan Hung

Department of pharmacy, College of Pharmacy, China medical University
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Phytomedicine
Verified
Journal Article
Closed access
YTYu-Ning Teng
Yu-Ning Teng
MSMing-Jyh Sheu
Ming-Jyh Sheu
YHYow-Wen Hsieh
Yow-Wen Hsieh
RWRuey-Yun Wang
Ruey-Yun Wang
YCYao-Chang Chiang
Yao-Chang Chiang
Chin-Chuan HungChin-Chuan Hung
Chin-Chuan Hung

7 January 2020 in Molecules
Verified
Journal Article
Open access
PDF file
YTYu-Ning Teng
Yu-Ning Teng
CWCharles C.N. Wang
Charles C.N. Wang
WLWei-Chieh Liao
Wei-Chieh Liao
YLYu Hsuan Lan
Yu Hsuan Lan
Chin-Chuan HungChin-Chuan Hung
Chin-Chuan Hung
Multidrug resistance (MDR) is a complicated ever-changing problem in cancer treatment, and P-glycoprotein (P-gp), a drug efflux pump, is regarded as the major cause. In the way of developing P-gp inhibitors, natural products such as phenolic acids have gotten a lot of attention recently. The aim of the present study was to investigate the modulating effects and mechanisms of caffeic acid on human P-gp, as well as the attenuating ability on cancer MDR. Calcein-AM, rhodamine123, and doxorubicin were used to analyze the interaction between caffeic acid and P-gp, and the ATPase activity of P-gp was evaluated as well. Resistance reversing effects were revealed by SRB and cell cycle assay. The results indicated that caffeic acid uncompetitively inhibited rhodamine123 efflux and competitively inhibited doxorubicin efflux. In terms of P-gp ATPase activity, caffeic acid exhibited stimulation in both basal and verapamil-stimulated activity. The combination of chemo drugs and caffeic acid resulted in decreased IC50 in ABCB1/Flp-InTM-293 and KB/VIN, indicating that the resistance was reversed. Results of molecular docking suggested that caffeic acid bound to P-gp through GLU74 and TRY117 residues. The present study demonstrated that caffeic acid is a promising candidate for P-gp inhibition and cancer MDR attenuation.

22 November 2018 in Molecules
Verified
Journal Article
Open access
PDF file
HCHsiu-Ju Chen
Hsiu-Ju Chen
YCYun-Lung Chung
Yun-Lung Chung
CLChia-Ying Li
Chia-Ying Li
YCYingTzu Chang
YingTzu Chang
CWCharles C.N. Wang
Charles C.N. Wang
Chin-Chuan HungChin-Chuan Hung
Chin-Chuan Hung
P-glycoprotein (P-gp) effluxes lots of chemotherapeutic agents and leads to multidrug resistance (MDR) in cancer treatments. The development of P-gp inhibitors from natural products provide a potential strategy for the beneficial clinical outcomes. This study aimed to evaluate the effects of the natural flavonoid taxifolin, luteolin, (−)-gallocatechin, and (−)-catechin on human P-gp activity. The kinetic interactions and underlying mechanisms of taxifolin-mediated transporter inhibition were further investigated. The transporter inhibition ability was evaluated in human P-gp stable expression cells (ABCB1/Flp-InTM-293) by calcein-AM uptake assays. The kinetics study for P-gp inhibition was evaluated by doxorubicin and rhodamine123 efflux assays. The MDR reversal ability of taxifolin were performed by SRB assays to detect the cell viability in sensitive cancer cell line (HeLaS3), and resistant cancer cell line (KB-vin). Cell cycle analysis and ABCB1 real-time RT-PCR were used for mechanical exploration. The results demonstrated that taxifolin decreased ABCB1 expression in a concentration-dependent manner. The function of P-gp was inhibited by taxifolin through uncompetitive inhibition of rhodamine 123 and doxorubicin efflux. The combination of taxifolin significantly resensitized MDR cancer cells to chemotherapeutic agents. These results suggested that taxifolin may be considered as a potential P-gp modulator for synergistic treatment of MDR cancers.

1 June 2020 in Phytomedicine
Verified
Journal Article
Closed access
YCYingTzu Chang
YingTzu Chang
YLYu-Chao Lin
Yu-Chao Lin
LSLijuan Sun
Lijuan Sun
WLWei-Chieh Liao
Wei-Chieh Liao
CWCharles C.N. Wang
Charles C.N. Wang
Chin-Chuan HungChin-Chuan Hung
Chin-Chuan Hung

1 February 2019 in Phytomedicine
Verified
Journal Article
Closed access
YCYing-Tzu Chang
Ying-Tzu Chang
CWCharles C.N. Wang
Charles C.N. Wang
JWJiun-Yi Wang
Jiun-Yi Wang
TLTsui-Er Lee
Tsui-Er Lee
YCYung-Yi Cheng
Yung-Yi Cheng
Chin-Chuan HungChin-Chuan Hung
Chin-Chuan Hung

19 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Chin-Chuan HungChin-Chuan Hung
Chin-Chuan Hung
MCMu-Han Chiou
Mu-Han Chiou
YTYu-Ning Teng
Yu-Ning Teng
YHYow-Wen Hsieh
Yow-Wen Hsieh
CHChieh-Liang Huang
Chieh-Liang Huang
HLHsien-Yuan Lane
Hsien-Yuan Lane
Methadone is a widely used substitution therapy for opioid addiction. Large inter-individual variability has been observed in methadone maintenance dosages and P-glycoprotein (P-gp) was considered to be one of the major contributors. To investigate the mechanism of P-gp’s interaction with methadone, as well as the effect of genetic variants on the interaction, Flp-In™-293 cells stably transfected with various genotypes of human P-gp were established in the present study. The RNA and protein expression levels of human P-gp were confirmed by real-time quantitative RT-PCR and western blot, respectively. Utilizing rhodamine 123 efflux assay and calcein-AM uptake study, methadone was demonstrated to be an inhibitor of wild-type human P-gp via non-competitive kinetic (IC50 = 2.17±0.10 µM), while the variant-type human P-gp, P-gp with 1236T-2677T-3435T genotype and P-gp with 1236T-2677A-3435T genotype, showed less inhibition potency (IC50 = 2.97±0.09 µM and 4.43±1.10 µM, respectively) via uncompetitive kinetics. Methadone also stimulated P-gp ATPase and inhibited verapamil-stimulated P-gp ATPase activity under therapeutic concentrations. These results may provide a possible explanation for higher methadone dosage requirements in patients carrying variant-type of P-gp and revealed the possible drug-drug interactions in patients who receive concomitant drugs which are also P-gp substrates.